| UHC Medicaid Medical & Drug | Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases – Community Plan Medical Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Natalizumab (Tyruko® & Tysabri®) – Community Plan Medical Benefit Drug Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Noncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds – Community Plan Medical Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Off-Label/Unproven Specialty Drug Treatment – Community Plan Medical Benefit Drug Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Pharmacogenetic Panel Testing – Community Plan Medical Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Private Duty Nursing Services (for Florida Only) – Community Plan Medical Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Private Duty Nursing Services – Community Plan Medical Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Qalsody® (Tofersen) – Community Plan Medical Benefit Drug Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Reblozyl® (Luspatercept-Aamt) – Community Plan Medical Benefit Drug Policy | 2026-08-01 |
| UHC Medicaid Medical & Drug | Roctavian® (Valoctocogene Roxaparvovec-Rvox) – Community Plan Medical Benefit Drug Policy | 2026-08-01 |